Formulation Development
Agenus Enters Clinical Collaboration With Nelum for Zalifrelimab Combination
Agenus Inc. recently announced that it has entered into a clinical collaboration with Nelum Corp. to evaluate the safety and efficacy of zalifrelimab, Agenus’ anti-CTLA-4 antibody….
PromoCell Receives EXCiPACT Certification as Manufacturer of Pharmaceutical Excipients to GMP Standards
PromoCell, one of the leading European manufacturers of human cell culture and cell biology products, has recently announced to have successfully completed a comprehensive EXCiPACT…
Vaxart Announces Additional Preclinical COVID-19 Oral Vaccine Data & Publication
Vaxart, Inc. recently announced additional results from its SARS-CoV-2 Hamster Challenge Study, as well as a peer-reviewed publication in Nature Medicine resulting from a collaboration…
DURECT Corporation Announces First Patient Dosed in Phase 2b AHFIRM Study
DURECT Corporation recently announced it has dosed the first patient in its AHFIRM randomized, double-blind, placebo-controlled, multi-center Phase 2b study to evaluate the safety and efficacy of DUR-928…
Antios Therapeutics Completes Phase 1b Clinical Trial of Active Site Polymerase Inhibitor Nucleotide
Antios Therapeutics, Inc. recently announced it has completed the Phase 1b clinical trial of ATI-2173, an Active Site Polymerase Inhibitor Nucleotide (ASPIN), in patients with…
Nexelis Acquires GSK Vaccines Clinical Bioanalytical Laboratory
Nexelis, a portfolio company of Ampersand Capital Partners, and a leading provider of advanced assay development and laboratory testing services in the infectious, oncologic, and metabolic diseases fields, has signed an asset purchase agreement with GSK to….
ViGeneron Announces Research Collaboration With Daiichi Sankyo to Evaluate Novel Ophthalmic Gene Therapy
ViGeneron GmbH recently announced a research collaboration to utilize its novel engineered adeno-associated virus (vgAAV) vectors with Daiichi Sankyo Company, Limited for delivering….
Molecular Templates Announces FDA Acceptance of IND Application for a PD-L1-Targeted Engineered Toxin Body Enabled With Proprietary Antigen Seeding Technology
Molecular Templates, Inc. recently announced the US FDA has accepted its Investigational New Drug (IND) application for MT-6402, a next-generation ETB targeting PD-L1 that is enabled with….
Clene Nanomedicine Receives Patent Notice of Allowance for using Gold Nanocrystals for Treating MS
Clene Inc. recently announced its wholly owned subsidiary Clene Nanomedicine, Inc., a clinical-stage biopharmaceutical company, was issued a Notice of Allowance from the US Patent and Trademark Office (USPTO) for its invention for….
Cognate BioServices & Its Gene Therapy Division Cobra Biologics Announce Major Expansion
Cobra Biologics, the gene therapy division of the Cognate BioServices’ group, recently announced a multi-phase augmentation of its plasmid DNA services as a continuation of…
Cocrystal Pharma Announces Further Development of Influenza A/B Antiviral Compounds by Merck Under Exclusive Worldwide License & Collaboration Agreement
Cocrystal Pharma, Inc. recently announced it has completed all research obligations under the Merck exclusive worldwide license and collaboration agreement, and that Merck is now…
Neuropathix Announces Publication of Its Global PCT Patent for a Novel Hops-Inspired Neuroprotectant
Neuropathix, Inc. recently announced the publication of its global WIPO/PCT Patent WO 2020/ 264324 – Use of Certain Phosphatidylcholines Containing Long Chain Polyunsaturated Fatty Acids…
Quantum Genomics Launches Phase 3 Pivotal REFRESH Study
Quantum Genomics recently announced the launch of its Phase 3 REFRESH study in difficult-to-treat or resistant hypertension. This new study is part of firibastat’s Phase…
Gritstone Advances Second-Generation COVID-19 Vaccine
Gritstone Oncology, Inc. recently announced it is advancing development of a second-generation vaccine against SARS-CoV-2, the virus that causes COVID-19, with potential for both prolonged…
Caladrius Biosciences Treats First Patient in the Phase 2b FREEDOM Trial
Caladrius Biosciences, Inc. recently announced it has treated the first patient in its Phase 2b FREEDOM trial of CLBS16 as a therapy for coronary microvascular…
Hovione Launches the Most Advanced Screening Service for Optimal Spray Dried Dispersions Formulation
Hovione, the leader in Pharmaceutical Spray Drying, recently announced the launch of ASD-HIPROS, a proprietary screening service for spray dried dispersions…..
BD Advances Immunology Research by Enabling Researchers to Investigate 30 Immune Markers in a Single Experiment
BD (Becton, Dickinson and Company) recently announced the commercial release of the BD AbSeq Immune Discovery Panel (IDP), a state-of-the-art, pre-titrated antibody-oligo-based discovery tool designed to….
AMRI Included in BARDA CDMO Network in Support of COVID-19 Pandemic Response in the US
Albany Molecular Research, Inc. recently announced its Albuquerque, NM, facility has been approved for inclusion in the Biomedical Advanced Research and Development Authority (BARDA) contract…
Catalent Agrees to Acquire Dry Powder Inhaler Spray Drying, Capsule Manufacturing & Packaging Capabilities From Acorda Therapeutics
Catalent recently announced it has entered into a definitive agreement to acquire the manufacturing and packaging operations of Acorda Therapeutics, Inc. The acquisition complements Catalent’s…
Seer Signs Commercial Agreement to Provide Complete End-to-End Solution for Unbiased, Deep, Rapid & Large-Scale Proteomics
Seer recently announced it has signed a non-exclusive commercial agreement with Thermo Fisher Scientific for Seer to offer Thermo Fisher’s Orbitrap Eclipse Tribid and Orbitrap…
